These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7513247)

  • 21. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
    Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
    El-Sherif WT; Makhlouf NA; El-Gendi SS; Hassan HI; Herdan OM
    Egypt J Immunol; 2012; 19(2):53-65. PubMed ID: 23885407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.
    Jinno K; Tanimizu M; Hyodo I; Nishikawa Y; Hosokawa Y; Doi T; Endo H; Yamashita T; Okada Y
    J Gastroenterol; 1998 Jun; 33(3):376-82. PubMed ID: 9658317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated renin levels in patients with liver cirrhosis and hepatocellular carcinoma.
    Lotfy M; El-Kenawy Ael-M; Abdel-Aziz MM; El-Kady I; Talaat A
    Asian Pac J Cancer Prev; 2010; 11(5):1263-6. PubMed ID: 21198274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis.
    Murawaki Y; Ikuta Y; Nishimura Y; Koda M; Kawasaki H
    J Gastroenterol Hepatol; 1996 May; 11(5):443-50. PubMed ID: 8743916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
    Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
    Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
    Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma.
    Ito N; Kawata S; Tamura S; Shirai Y; Kiso S; Tsushima H; Matsuzawa Y
    Cancer Lett; 1995 Feb; 89(1):45-8. PubMed ID: 7882301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.
    Ulu M; Alacacioglu A; Yuksel E; Pamukk BO; Bozkaya G; Ari A; Yuksel A; Sop G; Alacacioglu I
    Saudi J Gastroenterol; 2015; 21(1):47-50. PubMed ID: 25672239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
    Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
    Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma.
    Moussa YI; Plevris JN; Hayes PC
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):159-63. PubMed ID: 10741929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.
    Spadaro A; Ajello A; Luigiano C; Morace C; Resta ML; Berlinghieri G; Campo S; Scisca C; Alibrandi A; D'Arrigo G; Alessi N; Ferrau O; Freni MA
    World J Gastroenterol; 2006 Aug; 12(29):4716-20. PubMed ID: 16937445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma.
    Lee D; Chung YH; Kim JA; Lee YS; Lee D; Jang MK; Kim KM; Lim YS; Lee HC; Lee YS
    Oncology; 2012; 82(1):11-8. PubMed ID: 22269311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis.
    Yuen MF; Norris S; Evans LW; Langley PG; Hughes RD
    Scand J Gastroenterol; 2002 Feb; 37(2):233-8. PubMed ID: 11843063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.
    El-Shal AS; Zidan HE; Rashad NM; Wadea FM
    Cytokine; 2017 Aug; 96():75-86. PubMed ID: 28371666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
    Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
    Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.